Inhibrx Biosciences, Inc. (INBX) — Financial Flexibility Index
Inhibrx Biosciences, Inc. (INBX) has a Financial Flexibility Index of -0.19x as of March 2026. Free cash flow of $-38.03 Million (operating CF $-38.03 Million minus capex $0.00) represents 0% of total liabilities ($205.00 Million). Check INBX tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Inhibrx Biosciences, Inc. Financial Flexibility Index (2016–2025)
Historical Financial Flexibility Index trend for Inhibrx Biosciences, Inc. across 10 annual periods. For the full cash flow conversion analysis, see Inhibrx Biosciences, Inc. (INBX) cash conversion ratio.
Annual Financial Flexibility Index for Inhibrx Biosciences, Inc. (2016–2025)
Year-by-year free cash flow to debt coverage for Inhibrx Biosciences, Inc.. Explore Inhibrx Biosciences, Inc. (INBX) debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2025 | -0.94x | $-129.76 Million | $-129.79 Million | $138.49 Million | ▲ +77.0% |
| 2024 | -4.07x | $-191.81 Million | $-194.41 Million | $47.18 Million | ▼ -469.5% |
| 2023 | -0.71x | $-188.72 Million | $-193.31 Million | $264.39 Million | ▼ -45.0% |
| 2022 | -0.49x | $-114.61 Million | $-115.30 Million | $232.82 Million | ▲ +39.2% |
| 2021 | -0.81x | $-79.46 Million | $-80.32 Million | $98.07 Million | ▼ -18.7% |
| 2020 | -0.68x | $-46.60 Million | $-47.97 Million | $68.27 Million | ▼ -170.8% |
| 2019 | -0.25x | $-30.27 Million | $-32.08 Million | $120.06 Million | ▲ +21.3% |
| 2018 | -0.32x | $-21.66 Million | $-23.09 Million | $67.63 Million | ▲ +27.0% |
| 2017 | -0.44x | $-17.41 Million | $-18.75 Million | $39.67 Million | ▲ +50.9% |
| 2016 | -0.89x | $-17.89 Million | $-18.11 Million | $20.03 Million | — |